Horizon

Horizon was founded by Dr Chris Torrance and Professor Alberto Bardelli in 2007 when they came across an impressive gene editing platform, rAAV, which enabled the ability to tailor-make cell lines with virtually any genomic modification. Since then the company has grown rapidly, with offices in the UK, Europe and the U.S. Horizon now offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company’s own R&D pipeline.

www.horizondiscovery.com